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One of the problems of gene therapy of melanoma is effective exp ression of therapeutic gene in tumor cells and
their metastases but not in normal cells. In this review, we will consider a two-step approach to a highly specific
gene therapy. At the first step, therapeutic genes are delivered specifically to tumor cells using cell surface
markers of melanoma cells as targets. At the second step, a specific expression of the therapeutic genes in tumor
cells is ensured. Surface markers of mela-noma cells were analyzed as potential targets for therapeutic treat-
ment. Criteria for choosing the most promising targets are proposed. The use of specific melanoma promoters
allows to further increase the specificity of treatment via transcriptional control of therapeutic gene expression
in melanoma cells.
Keywords: gene therapy, cell surface markers, melanoma-specific promoters, melanoma.
In recent years the number of patients with malignant
melanoma, one of the most aggressive tumors, has been
increasing worldwide. One of the main melanoma
specificities is early metastasis which results in high
mortality rate of patients: survival rate of patients in the
course of five years after the beginning of the disease is
up to 50%. Due to this fact the therapy for melanoma is
related to many hardships, including difficulty of
recognizing metastases and high resistance of
melanoma cells which conditions poor diagnosis of
disease progress [1, 2]. Up-to-now the main method of
therapy for melanoma has been surgical resection of
affected tissues. Chemo- and radiotherapy prove to be
of little effect, as melanoma metastases are often
resistant to this treatment [2]. Due to this fact gene
therapy suggests new approaches, based on reinforcing
the specificity of affecting target malignant cells while
decreasing the impact of medicine on healthy cells.
One of the main problems of efficient application of
therapeutic agents of post-genome generation is the
absence of optimal methods of therapeutic gene
(transgene) delivery into malignant cells. This problem
may be solved using specific surface markers of
melanoma cells, bound to ligands, introduced into the
composition of a delivering vector. On the other hand,
tumor specificity may be added while creating
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conditions for transgene transcription only in specific
tissues. In order to meet the second condition,
promoters and enhancers, specific for a certain tumor
type, are used in constructing therapeutic vectors [3, 4].
The advantage of using promoters and other regulatory
elements, specific only for this tumor, is maximal
decrease of side effects. However, promoters, working
well in a primary tumor, do not always retain this
specificity in its metastases. Therefore, the application
of promoters, working in a wide range of tumors, but
not in normal cells, seems very promising. These
constructions may be universal for therapy of different
types of tumors. The combination of target delivery
and specific gene expression may contribute
considerably to enhancing safety of the therapeutic
system.
This review describes markers with increased
concentration on the surface of melanoma cells but
almost absent on normal non-tumor cells. Special
attention is paid to changes in expression profile of
melanoma markers in metastases. The possibility of
their application for specific recognition of malignant
cells while delivering genetic material is considered.
There are presented data on surface antigens of
melanoma stem cells, promising targets of antitumor
therapy. Besides, the structures and features of
promoters, specific for melanoma cells as well as
promoters, active in a wide range of tumors, are
described; the possibility of their application for the
purposes of gene therapy for melanoma is discussed.
Surface markers of melanoma. . Surface markers
of melanoma cells have been used as subjects of
decades-long studies [5, 6]. The most significant ones
are presented below.
Antigens, recognized by cytotoxic
T-lymphocytes. Melanoma cells synthesize various
antigens, recognized by autologous and specific
cytotoxic T-lymphocytes (CTL) when presented in
molecular complex with MHC molecules [7]. Some
antigens are suitable targets for immune therapy.
Antigens, presented on the surface of melanoma
cells, may be divided into four classes [8]. The first
class is presented by antigens of melanocyte
differentiation. It is comprised of such proteins as
tyrosinase (TYR), MLANA, SILV, TRP-1 and TRP-2
[9-11]. Antigens of this class play a key role in the
development of melanocytes and have restricted tissue
specificity. Transcription of genes, coding proteins of
this class, is observed only in melanocytes, in cells of
nevus and pigment spots as well as in melanoma cells.
High level of such antigens in pigment spots and nevus
does not allow distinguishing melanoma cells from
non-carcinogenic cells of melanocyte lineage [12].
However, these antigens may serve as highly sensitive
diagnostic markers for determination of melanoma
cells in blood and metastases [13] and as good targets
for therapy of metastases.
The second class is comprised of cancer/testis
antigens. They are specific for embryonic cells and are
usually absent in tissues of an adult organism, except
for testes and placenta [14, 15]. However, these
antigens are considerably present in tumors of different
histological origin, including melanomas [16].
Cancer/testis antigens are encoded by three families of
genes, expressing them, – MAGE, BAGE and GAGE.
Melanoma cells present at least one of specified
antigens. Up-to-now the functions of these antigens
have not been studied sufficiently. It is supposed that
they are involved into the regulation of a cellular cycle
and apoptosis [14-16]. Genes CTAG1B (NY-ESO-1)
and LAGE-1 belong to the second group of cancer/testis
antigens [17]. The level of transcription of genes
NY-ESO-1/LAGE-1 in testes and placenta is very high,
while it is low in heart, skeletal muscles and pancreas,
and gene expression is not detected in other tissues.
Increased expression of gene NY-ESO-1 is observed in
some types of cancer, in particular, in melanoma cells,
and depends on the stage of disease. Increased
expression of NY-ESO-1 is associated with poor
prognosis for the disease progression [18].
Also, the family of SSX, numbering five
representatives, belongs to cancer/testis antigens.
Usually they all are expressed in testes; trace amounts
are expressed in thyroid gland and detected in many
types of cancer [19]. Transcription of gene SSX2 is
especially intense at melanoma [20].
Antigens, belonging to two other classes, present on
the surface, which are peptide fragments or proteins,
the contents of which is considerably increased in
different types of tumors (for instance, BIRC5,
MUC1/2, AFP and EphA2) as well as tumor-specific
antigens, occurring due to point mutations of
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widely-spread genes (p53, Ras, CDK4, MUM1,
CTNNB1, CDKN2B/INK4, etc.), are not unique for
melanoma cells, and the research thereof is far beyond
the framework of this review.
Antigens, predominantly synthesized by
melanoma cells. A distinguished group is comprised by
surface antigens, the expression of which is specific only
for melanoma cells and their metastases. At present there
are data about only two of these antigens – MIA
(melanoma-inhibiting activity) and MELOE
(melanoma-overexpressed antigen). The protein of
melanoma-inhibiting activity plays a significant role in
invasion and metastasis of melanomas and is deemed as
a highly specific and sensitive marker. The expression of
MIA gene is found mainly in melanoma, in
inconsiderable amounts – in chondrosarcomas,
carcinomas of ovaries and kidneys, in cancer of
head/neck and is absent in cells of normal skin and nevus
[21, 22]. Recently characterized antigen MELOE is
specific only for melanoma cells, it has not been detected
in other tissues and tumors. The functions and
specificities of this antigen are still unknown [23, 24].
An important factor of melanoma treatment is the
delivery of therapeutic genes into metastases. For this
reason it is essential to understand in what way the sets
of surface markers change in the range of tumors –
metastases. The analysis of expression profiles of
antigens, described above, demonstrated that
differentiation antigens SILV, MLANA, TYR in
samples of both primary tumors and metastases are at
the same level. At the same time cancer/testis antigens
MAGE1, MAGE4, NY-ESO-1 are found in primary
tumors less often and in smaller amounts than in
metastases [25], therefore, they may be targets of
therapeutic treatment both in primary tumors and
metastases. It was found that the expression of gene
MIA increases with the progression of melanoma [26].
Highly specific expression of cancer/testis antigens
and antigens of melanocyte differentiation makes them
good targets for delivery of gene therapeutic
constructions. On the other hand, the unique nature of
genetic regulatory apparatus of these genes may be
used for the purpose of expression of therapeutic genes
in melanomas only.
Melanoma cells receptors are capable of ensuring
selective penetration of therapeutic constructions into
required cells due to internalization of the receptor.
Many reviews are devoted to them [27, 28]. In this
review we will dwell upon description of two factors
only – melanocortin and tyrosine-kinase (c-Met)
receptors, since they are the most promising targets for
directed delivery of preparations.
Melanocortin 1 receptor (MC1R). . Five different
melanocortin receptors with specific distribution of
expression in human tissues were characterized [29].
Only receptor--melanocyte-stimulating hormone
(MC1R) is expressed in melanocytes and melanoma
cells. High expression of MC1R is also notable for cell
lines from primary and metastatic melanomas, while
only minor quantities of this receptor are found in some
other tissues and cells [30, 31]. MC1R receptor is
mainly localized inside cells; its amount increases on
the surface of cells for metastatic and uveal melanomas
[30]. The exposure of MC1R on the surface of cells is
induced by some cytokines, like interferon  (IFN-),
tumor necrosis factor  (TNF-), interleukins IL-4 and
IL-10 [32]. MC1R receptor has very close affinity to
such ligands as adrenocorticotropic and
melanocyte-stimulating hormones, capable of specific
internalization by cells [32, 33]. Therefore, this
receptor may be considered as a candidate for directed
delivery of preparations into melanoma cells.
c-Met receptor (HGFR). . Hepatocyte growth
factor receptor c-Met (HGFR) is synthesized in
epithelial cells and plays an important role in
embryonic development. A natural receptor ligand is
hepatocyte growth factor (HGF), the expression of
which is also observed in melanoma cells, which results
in activation of c-Met receptor, regulating signalling
pathways of MAPK and PI3K [34]. High expression of
c-Met in primary melanomas stimulates invasive
growth of malignant cells and enhances their metastatic
potential. Autocrine regulation of HGF/c-Met is
important for melanoma development, thus, the
disorder in ligand-receptor interaction may cause
suppression of melanoma growth [36]. It was shown
that antibodies with high affinity to HGF block the
binding of the latter to the ligand, inhibit
phosphorylation of c-Met, cell proliferation and
invasion of tumor cells [37]. While HGF interacts with
the receptor, the latter is internalized [38], which
enables the application of c-Met as a receptor for the
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introduction of therapeutic agents into the cells if the
analogue of HGF ligand is included into the
composition of the vector.
Molecules of intracellular interaction.The
development of many types of tumors, including
melanoma, is accompanied by disorders in expression
of genes, coding for cell adhesion proteins [39]. The
changes in qualitative and quantitative composition of
cell adhesion molecules may serve as prognostic
feature of malignization. The cell adhesion molecules
(CAM) are presented by a wide class of proteins,
divided into families of immunoglobulins, cadherins,
selectins, integrins and mucines [40]. The example
thereof may be found in proteins of subfamily of CAM
immunoglobulins, such as MCAM (CD146, MUC18),
L1CAM (CD171), ALCAM (CD166), ICAM1
(CD54), and CEACAM1 (CD66a). Their content is not
high in normal melanocytes [39]. During malignization
the expression of corresponding genes is constantly
increasing, reaching its maximum in metastatic
melanoma cells, which promotes the increase in the
invasiveness and motility of melanoma cells and the
increase in the metastasis level [39, 41, 42]. It is
supposed that the majority of cell adhesion molecules
condition high metastatic activity of melanoma, and in
some cases they are the main effectors of metastasis
formation [42]. Considerable density of the mentioned
receptors on the surface of melanoma cells makes them
a promising target for directed delivery of transgenes.
A characteristic feature of the majority of the
mentioned cell adhesion molecules is their capability
of internalization, which may ensure efficient
introduction of the receptor-related vector into the cell
[43, 44].
Melanoma-associated antigen with high
molecular weight. Significant expression of the gene,
coding melanoma-associated antigen with high
molecular weight (HMW-MAA), is observed only in
melanoma cells and in human melanoma cell lines, but
it has not been discovered in normal melanocytes, cells
of nevus and pigment spots [45]. The studies of recent
years have proven HMW-MAA participation in the
activation of some signalling pathways, modulating
adhesion, migration, and invasion of melanoma cells
[45, 46]. The capability of HMW-MAA to internalize
inside the cell was discovered [47].
Surface markers of melanoma stem cells. . A vast
volume of experimental data testifies to the fact that
among malignant melanoma cells there is a small
population of stem cells, capable of their own
reproduction and formation of a tumor [48-51]. This
cell population is considered to be the most aggressive.
Melanoma stem cells are supposed to be the very
providers of resistance to practically all the kinds of
chemotherapy [50, 52]. Several surface markers of
melanoma stem cells were revealed and characterized.
One of them – membrane marker CD133 – was
discovered in less than 1% of melanoma cells, and these
cells had the greatest oncogenic potential [48, 49].
Other markers are P-glycoproteins (ABCB5 and
ABCG2), related to MDR family – ATP-dependent
transporter proteins, conferring chemoresistance to
melanoma cells [52, 53]. The level of expression for
ABCB5 gene is considerably higher in melanoma cells
than in nevus [53]. Proteins MHCI and
melanoma-specific antigens NY-ESO-1 and MAGE-A
are considerably less presented in ABCB5-positive
cells [54]. It was recently shown that CD271
marker-positive cells have the greatest potential for
melanoma development [50]. These cells have sharp
decrease in expression of genes TYR, MART1 and
MAGEC1/MAGEC2. This fact may serve as
explanation of the failures in melanoma therapy using
antibodies to protein products of the mentioned genes.
However, contrary results were published almost at the
same time, demonstrating the greatest oncogenic
potential of cells without CD271 [55].
The review [51] suggests heterogeneity of
melanoma stem cells and the possibility of existence of
cells with different phenotype, carrying different
markers in specific conditions. It is supposed that the
occurrence of metastases is possible due to migration of
carcinogenic stem cells into organs with suitable
conditions for their binding. A number of works
described the increase in the content of tumor stem cell
markers during metastases [50]. There are reasons to
believe that therapy for tumors should mainly be
directed at the suppression of stem cells.
The use of surface markers of melanoma for
directed delivery of therapeutic genes. Up-to-now
there are only several known ways of using receptors
and surface antigens of melanoma for the therapy of
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this disease. For instance, it was suggested to use the
process of cell internalization of toxic preparations,
conjugated with specific melanoma markers, for
therapy purposes. Promising results were received
while using gelonin conjugates with antibodies to
HMW-MAA [56]. Melanoma receptors may serve as
targets of oncolytic viruses, in particular, Coxsackie
virus A21, interacting with ICAM1 receptor [57]. The
majority of receptors are present on many normal cells,
therefore it is necessary to choose receptors with
enhanced expression in melanoma cells proper. The
development of methods for identification and
destruction of metastases is of great relevance for
melanoma treatment. The first priority is attributed to
the study of the content of stem cells markers and
receptors in melanoma cells and metastases, and the
possibility of their application for therapeutic purposes.
Besides, it is necessary to search for new marker genes,
which could be used for directed impact on metastases.
Promoters that specifically active in melanoma
cells. Specificity to a certain type of tissue in the
process of creating gene therapeutic constructions is
conditioned by the level of expression of transgene,
dependent on regulatory systems, in particular,
enhancers and promoters, active only in carcinogenic
cells. At present promoters of genes of tyrosinase and
melanoma-inhibiting activity are the most studied and
used for gene therapy of melanoma, sometimes in
combination with distal elements of other promoters
and/or enhancers. Structures of both human and murine
promoters TYR and MIA are studied and described in
fine detail [58-60]. Functional comparison proved that
human TYR promoter demonstrates less efficiency and
specificity of expression in human melanocytes
compared to murine promoter. The enhancer has a
greater impact on the activity of human TYR promoter,
while the promoter itself is important just for the
manifestation of specific activity of a murine gene [58,
61, 62].
A number of works are devoted to description of
various combinations of tyrosinase promoter with
transcription-controlling cys-regulatory elements –
heterologous enhancers; their impact on the specificity
of transgene expression in melanoma cells was
established [58]. The greatest enhancing effect on the
activity and specificity of human TYR promoter is made
by binding of several enhancers of murine Tyr. Human
enhancing sequences in the same constructions
condition only 2-3-fold increase in reporter gene
activity [61]. Up-to-now nothing is known about
enhancer elements of gene MIA. It was shown that
contrary to promoter of TYR gene, the activity of
promoter of human MIA gene increases with melanoma
progression [60]. The study of the impact of murine Tyr
enhancers on the activity of murine Tyr promoter and
human MIA revealed that the binding of several
enhancers of tyrosinase gene toMIA promoter results in
considerable increase in the specific activity of the
latter in cells of melanoma lines. Similar to the
tyrosinase promoter, murine enhancers have a much
higher activity compared to enhancers of human
tyrosinase [63]. The inhibition of melanoma cell
growth using MIA promoters with four murine Tyr
enhancers is slightly less considerable than the effect of
a strong constitutive promoter CMV which does not
ensure selective expression of the transgene [64].
The data presented demonstrate that the application
of different combinations of promoters and enhancers
confer high efficiency of expression of transgenes in
melanoma cells and may solve the problem of
specificity during the therapy of this disease [63, 64].
The promoter of MIA gene is of special interest, since,
contrary to TYR gene, it is expressed only in cells of
malignant melanoma, and not in other cells of
melanocyte lineage.
It is noteworthy to pay attention to the structure and
features of the promoter of melanocortin receptor gene.
Similar to TYR and MIA, melanocyte-specific
expression of MC1R is activated while binding the
transcription factor MITF [65]. 150 b.p. above
ATG-codon are sufficient to initiate
melanocyte-specific transcription [66]. The minimal
promoter of MC1R gene may be a promising candidate
for the control of transgene expression in melanoma
cells. Up-to-now there is no data on the application of
this promoter while creating therapeutic constructions.
Promoters specifically active in many types of
tumor cells The instances of the best known tumor
specific promoters (TSP) are promoters of TERT,
Cox-2 and BIRC5 genes. These promoters are notable
for increased expression of genes, controlled by them,
in many types of tumors, including melanoma,
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compared to the expression in normal tissues [67–69].
For instance, the study of activity of transgenes in cells
of melanoma lines, when recombinant adenoviruses
were used as vectors, demonstrated that the activity of
BIRC5 promoter in normal melanocytes proved to be
considerably lower compared to melanoma cells [70].
Using BIRC5 promoter to control the expression of
gene of sodium-iodide symporter (NIS), the cells of
melanoma line A375 acquire the capability of
absorbing radioactive iodine-131 which results in their
death, while normal fibroblasts, transfected by the same
construction, do not absorb iodine and do not perish
[71]. Therefore, BIRC5 promoter shows high
tumor-specificity and has good perspectives for its
application in therapy for melanoma. However, the
majority of TSP have low activity compared to such
constitutive strong promoters as SV40 and CMV [71,
72]. There is considerable variability of activity among
TSP, depending on the type of carcinogenic cells. In
particular, the activity of BIRC5 promoter in different
tumor cell lines varies in the range of 0.3-16% from the
activity of CMV promoter, while the efficiency of
TERT promoter may differ 20-fold depending on the
cancer cells line [72, 73].
Creation and application of chimeric promoters.
One of methods of constructing specific promoters with
sufficient transcriptional potential, which are short
enough to combine with delivery vectors, is the
creation of synthetic and/or double (chimeric)
promoters. To obtain specific promoter modules de
novo, characterized promoters and fragments of
regulatory sequences are used. For instance, artificial
promoters were constructed on the basis of promoter
elements of human TYR gene and -fetoprotein
(AFP1), notable for strong and specific expression in
the melanoma cell lines [74]. The presence of
conservative M-box is remarkable for
melanocyte-specific promoters. GRE element and
AP1-binding element, specific for the cell cycle, are
located in 5'-region of AFP1 promoter. Different
combinations of the same copy or several copies of TYR
and AFP1 promoter fragments – M-box, AP1- and
GRE-elements – were used to obtain several efficient
specific promoters and to show their selective activity
in the melanoma B16 cell line, but not in the HeLa cells
[74]. The activity and specificity of synthetic promoters
depend on selected optimal number of regulatory
elements. In this case the highest efficiency is
demonstrated by the construction of a promoter with
three GRE elements, three AP1 elements and two
M-boxes with length of about 300 b.p. [74].
The application of hybrid double promoters, one of
which is cancer-specific and the other – strong
non-specific, or each promoter is tumor-specific,
allows enhancing the efficiency of promoters. The
example thereof may be found in chimeric promoter
CMV-TERT, which was created among the first ones
[75]. The hybrid construction was obtained on the basis
of promoter of human telomerase reverse transcriptase
(TERT) and minimal promoter of cytomegalovirus
(CMV). This promoter has higher activity than
non-modified promoter TERT with preservation of
tumor-specificity. Recently the application of other
double tumor-specific promoters has also been
described [76–78]. The possibility of applying these
constructions was shown for the increase in efficiency
of transgene expression in the treatment of small-cell
lung cancer and breast cancer. The mentioned
technology allows reaching a high level of expression
of the therapeutic gene in tumor cells, preserving
tumor-specificity. Besides, a number of studies
demonstrated that the application of double promoters
allows obtaining more universal constructions ensuring
transgene expression in many types of malignant cells
[76, 78]. At present there are no described systems of
double melanoma-specific promoters. However, the
creation of constructions on the basis of
melanoma-specific promoters, like promoters of MIA,
TYR and MC1R genes, may allow ensuring universal
and highly efficient expression of transgenes in
melanoma cells.
The application of promoters in gene therapy for
melanoma. There are two possible approaches to the
application of tumor-specific promoters for gene
therapy. The first approach is related to influencing
targets – specific molecular components, playing a
critical role in carcinogenesis, while the second one is
aimed at searching for possibilities of total destruction
of tumors. The heterogeneous structure of tumors
implies giving preference to the second approach to
gene therapy development, usually called suicide
therapy [79, 80]. The method of suicide gene therapy is
8
ALEKSEENKO I. V., ZINOVYEVA M. V., PLESHKAN V. V., SVERDLOV E. D.
based on the introduction into a malignant cell a gene
encoding an enzyme that absent in normal cell and is
capable of transforming a non-toxic for normal cells
prodrug into the toxin, causing selective death of cancer
cells only [80, 81]. The best known and frequently used
genes are genes of herpes simplex virus of thymidine
kinase (HSVtk) and yeast cytosine deaminase (FCY1).
Other killer genes have also been described [82]. The
success of applying suicide genes depends on bystander
effect to a high degree [40].
Conclusions. Successful application of gene
therapy requires selective delivery of therapeutic genes
into tumor cells and non-toxicity of these genes for
normal cells. Besides, there should be systemic
delivery, ensuring the penetration of agents into both
primary tumors and metastases, as well as the
possibility of quantitative destruction of tumor cells
and metastases [83, 84]. The reviewed surface markers
of melanoma cells may be applied for the delivery of
gene therapy constructions into tumor cells. The
delivery of the construction due to binding with surface
cell receptor, capable of internalizing by the cell during
the interaction with the ligand, seems to be the most
efficient [83]. However, as stated above, surface
markers are not strictly specific for melanoma cells and
are found on the surface of normal cells, although with
less density.
Moreover, tumor cells are capable of changing the
spectrum of surface determinants to avoid the immune
response. Therefore, promoters and enhancers,
working specifically in tumors of this tissue, are used to
increase the specificity of drug delivery and to decrease
side effects on normal cells while constructing vectors
[3, 4]. As for melanoma these are promoters and
enhancers of genes, involved into the process of
melanin synthesis. The second variant is the application
of more universal tumor-specific promoters, capable of
working in a wide range of tumors, but not in normal
cells. The suitability of therapeutic constructions for
melanoma metastases should be taken into account
during their development. The combined application of
specific promoters and their regulatory elements during
the development of gene constructions and surface
markers of melanoma cells for the penetration of
preparations into the target cells may prove to be a very
promising approach to control this fatal disease. The
efficiency of applying transgenes may be increased
using bystander effect, during which on receiving a
therapeutic construction the cancer cells produce a
specific product, toxic for neighboring cancer cells, but
not toxic for normal cells. According to the known data,
in order to destroy all the tumor cells, it is sufficient for
the gene to penetrate only 10% of tumor cells [40].
The methods, described in the review, are at the
stage of development, when the most suitable
regulatory elements are selected and the constructions
are created on their basis. New vectors are matched
using both natural viruses and the artificially obtained
systems of packing genetic material. It is possible that
this development will bring about a simple and efficient
system of eliminating melanomas and its metastases.
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Ðåçþìå
Îäíîé èç ïðîáëåì ãåííîé òåðàïèè çëîêà÷åñòâåííîé ìåëàíîìû ÿâ-
ëÿåòñÿ öåëåíàïðàâëåííàÿ ýêñïðåññèÿ òåðàïåâòè÷åñêîãî ãåíà â
îïóõîëåâûõ êëåòêàõ è èõ ìåòàñòàçàõ ïðè ìèíèìèçàöèè åå â íîð-
ìàëüíûõ êëåòêàõ. Â îáçîðå ðàññìîòðåí äâóõýòàïíûé ïîäõîä ê
âûñîêîñïåöèôè÷íîé òåðàïèè. Íà ïåðâîì ýòàïå îñóùå- ñòâëÿåò-
ñÿ àäðåñíàÿ äîñòàâêà òåðàïåâòè÷åñêèõ ãåíîâ â îïóõîëåâûå êëåò-
êè ñ èñïîëüçîâàíèåì â êà÷åñòâå ìèøåíè ïîâåðõíîñòíûõ ìàðêåðîâ
ìåëàíîìíûõ êëåòîê, íà âòîðîì – îáåñïå÷èâàåòñÿ ñïåöèôè÷-
íîñòü ýêñïðåññèè ãåíîâ â îïóõîëåâûõ êëåòêàõ. Ïðîâåäåí àíàëèç
ïîâåðõíîñòíûõ ìàðêåðîâ ìåëàíîìíûõ êëåòîê ñ òî÷êè çðåíèÿ ïðè-
ìåíåíèÿ èõ êàê ìèøåíåé äëÿ òåðàïåâòè÷åñêîãî âîçäåéñòâèÿ.
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Ïðåäëîæåíû êðèòåðèè âûáîðà íàèáîëåå ïåðñïåêòèâíûõ ìèøå-
íåé. Èñïîëüçîâàíèå ïðîìîòîðîâ, àêòèâíûõ òîëüêî â ìåëàíîìíûõ
êëåòêàõ, ïîçâîëÿåò åùå áîëüøå óâåëè÷èòü ñïåöèôè÷íîñòü âîçäå-
éñòâèÿ çà ñ÷åò êîíòðîëÿ òðàíñêðèïöèè òåðàïåâòè÷åñêèõ ãåíîâ â
òàêèõ êëåòêàõ.
Êëþ÷åâûå ñëîâà: ãåííàÿ òåðàïèÿ, ïîâåðõíîñòíûå ìàðêåðû,
ïðîìîòîðû, ìåëàíîìà.
². Â. Àëåêñåºíêî, Ì. Â. Ç³íîâ’ºâà, Â. Â. Ïëåøêàí, ª. Ä. Ñâåðäëîâ
Àäðåñíà äîñòàâêà òåðàïåâòè÷íèõ ãåí³â
ïðè ë³êóâàíí³ ìåëàíîìè:
ðîëü ïîâåðõíåâèõ ìàðêåð³â ³ ñïåöèô³÷íèõ ïðîìîòîð³â
Ðåçþìå
Îäí³ºþ ç ïðîáëåì ãåííî¿ òåðàï³¿ çëîÿê³ñíî¿ ìåëàíîìè º ö³ëåñïðÿ-
ìîâàíà åêñïðåñ³ÿ òåðàïåâòè÷íîãî ãåíà â ïóõëèííèõ êë³òèíàõ ³ ¿õ-
í³õ ìåòàñòàçàõ çà ì³í³ì³çàö³¿ ¿¿ ó íîðìàëüíèõ êë³òèíàõ. Â îãëÿä³
ðîçãëÿíóòî äâîåòàïíèé ï³äõ³ä äî âèñîêîñïåöèô³÷íî¿ òåðàï³¿. Íà
ïåðøîìó åòàï³ çä³éñíþºòüñÿ àäðåñíà äîñòàâêà òåðàïåâòè÷íèõ
ãåí³â ó ïóõëèíí³ êë³òèíè ç âèêîðèñòàííÿì ÿê ì³øåí³ ïîâåðõíåâèõ
ìàðêåð³â ìåëàíîìíèõ êë³òèí, íà äðóãîìó – çàáåçïå÷óºòüñÿ ñïå-
öèô³÷í³ñòü åêñïðåñ³¿ ãåí³â ó ïóõëèííèõ êë³òèíàõ. Ïðîâåäåíî àíà-
ë³ç ïîâåðõíåâèõ ìàðêåð³â ìåëàíîìíèõ êë³òèí ç òî÷êè çîðó çàñòî-
ñóâàííÿ ¿õ ÿê ì³øåíåé äëÿ òåðàïåâòè÷íî¿ ä³¿. Çàïðîïîíîâàíî êðè-
òåð³¿ âèáîðó íàéïåðñïåêòèâí³øèõ ì³øåíåé. Âèêîðèñòàííÿ ïðîìî-
òîð³â, àêòèâíèõ ëèøå â ìåëàíîìíèõ êë³òèíàõ, äîçâîëÿº çá³ëüøè-
òè ñïåöèô³÷í³ñòü ä³¿ çà ðàõóíîê êîíòðîëþ òðàíñêðèïö³¿ òåðàïåâ-
òè÷íèõ ãåí³â ó òàêèõ êë³òèíàõ.
Êëþ÷îâ³ ñëîâà: ãåííà òåðàï³ÿ, ïîâåðõíåâ³ ìàðêåðè, ïðîìîòî-
ðè, ìåëàíîìà.
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